Barclays lowered the firm’s price target on Solid Biosciences (SLDB) to $9 from $10 and keeps an Overweight rating on the shares. The company’s Q3 brought “encouraging” interim data for SGT-003 with a 58% microdystrophin protein level in 10 patients, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Reports Q3 2025 Results and Clinical Progress
- Solid Biosciences Reports Positive Interim Data on SGT-003
- Solid Biosciences reports Q3 EPS (48c), consensus (44c)
- Solid Biosciences Advances Gene Therapy Study for Friedreich’s Ataxia
- Solid Biosciences Advances Duchenne Gene Therapy with SGT-003 Study